

Luis Masana MarÃ- n

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2772743/publications.pdf>

Version: 2024-02-01

272
papers

20,584
citations

38660

50
h-index

11288

136
g-index

305
all docs

305
docs citations

305
times ranked

20071
citing authors

#	ARTICLE	IF	CITATIONS
1	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011, 32, 1769-1818.	1.0	2,767
2	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017, 38, 2459-2472.	1.0	2,292
3	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2013, 34, 3478-3490.	1.0	2,132
4	Lipoprotein(a) as a cardiovascular risk factor: current status. <i>European Heart Journal</i> , 2010, 31, 2844-2853.	1.0	1,392
5	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <i>European Heart Journal</i> , 2011, 32, 1345-1361.	1.0	993
6	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2014, 35, 2146-2157.	1.0	835
7	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020, 41, 2313-2330.	1.0	776
8	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. <i>European Heart Journal</i> , 2015, 36, 2425-2437.	1.0	644
9	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 655-666.	5.5	473
10	Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. <i>Vascular Health and Risk Management</i> , 2009, 5, 757-65.	1.0	421
11	Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. <i>Atherosclerosis</i> , 2014, 232, 346-360.	0.4	419
12	EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1279-1289.	0.8	369
13	Abnormalities of Lipoprotein Metabolism in Patients with the Nephrotic Syndrome. <i>New England Journal of Medicine</i> , 1990, 323, 579-584.	13.9	275
14	Comparison of Genetic Versus Clinical Diagnosis in Familial Hypercholesterolemia. <i>American Journal of Cardiology</i> , 2008, 102, 1187-1193.e1.	0.7	153
15	Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy. <i>Journal of Lipid Research</i> , 2015, 56, 737-746.	2.0	133
16	Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: Possible contribution of phospholipase A2 to this atherogenic profile. <i>Arthritis and Rheumatism</i> , 2001, 44, 2761-2767.	6.7	125
17	Low HDL and high triglycerides predict COVID-19 severity. <i>Scientific Reports</i> , 2021, 11, 7217.	1.6	122
18	Atherosclerosis in Patients Infected With HIV Is Influenced by a Mutant Monocyte Chemoattractant Protein-1 Allele. <i>Circulation</i> , 2004, 110, 2204-2209.	1.6	121

#	ARTICLE	IF	CITATIONS
19	Evidence of hypolipemiant and antioxidant properties of argan oil derived from the argan tree (<i>Argania spinosa</i>)*1. <i>Clinical Nutrition</i> , 2004, 23, 1159-1166.	2.3	116
20	Gene expression analysis of a human enterocyte cell line reveals downregulation of cholesterol biosynthesis in response to short-chain fatty acids. <i>IUBMB Life</i> , 2008, 60, 757-764.	1.5	98
21	Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility Commentary: Early discontinuation violates Helsinki principles. <i>BMJ: British Medical Journal</i> , 2001, 322, 603-606.	2.4	93
22	Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. <i>Aids</i> , 2002, 16, 1383-1389.	1.0	92
23	Combination lipid-lowering therapy as first-line strategy in very high-risk patients. <i>European Heart Journal</i> , 2022, 43, 830-833.	1.0	92
24	Exogenous FABP4 increases breast cancer cell proliferation and activates the expression of fatty acid transport proteins. <i>Molecular Carcinogenesis</i> , 2017, 56, 208-217.	1.3	89
25	Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease. <i>Journal of Endocrinology</i> , 2017, 233, R173-R184.	1.2	86
26	Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. <i>Current Medical Research and Opinion</i> , 2004, 20, 1437-1445.	0.9	85
27	Effect of nut consumption on oxidative stress and the endothelial function in metabolic syndrome. <i>Clinical Nutrition</i> , 2010, 29, 373-380.	2.3	85
28	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. <i>Atherosclerosis Supplements</i> , 2014, 15, 1-15.	1.2	83
29	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. <i>Atherosclerosis</i> , 2021, 325, 99-109.	0.4	83
30	Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. <i>Journal of Lipid Research</i> , 2008, 49, 1746-1751.	2.0	80
31	Relationship between hepatic lipid peroxidation and fibrogenesis in carbon tetrachloride-treated rats: effect of zinc administration. <i>Clinical Science</i> , 1992, 83, 695-700.	1.8	72
32	The Role of Immunity and Inflammation in the Progression of Atherosclerosis in Patients With HIV Infection. <i>Stroke</i> , 2007, 38, 2477-2484.	1.0	72
33	Apolipoprotein E Polymorphism and Serum Concentration in Alzheimer's Disease in Nine European Centres: the ApoEurope Study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 721-30.	1.4	70
34	Oleic Acid Rich Diet Protects Against the Oxidative Modification of High Density Lipoprotein. <i>Free Radical Biology and Medicine</i> , 1997, 22, 1037-1045.	1.3	69
35	Plant sterol-enriched fermented milk enhances the attainment of LDL-cholesterol goal in hypercholesterolemic subjects. <i>European Journal of Nutrition</i> , 2008, 47, 32-39.	1.8	69
36	IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"? <i>Atherosclerosis</i> , 2015, 240, 161-162.	0.4	64

#	ARTICLE	IF	CITATIONS
37	Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 157-164.	1.4	64
38	Unsaturated fatty acids and their oxidation products stimulate CD36 gene expression in human macrophages. <i>Atherosclerosis</i> , 2002, 164, 45-56.	0.4	63
39	Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. <i>Atherosclerosis</i> , 2007, 194, 175-181.	0.4	62
40	Fatty acid-binding protein 4 impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells. <i>Cardiovascular Diabetology</i> , 2012, 11, 72.	2.7	62
41	Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia. <i>Atherosclerosis</i> , 2012, 222, 449-455.	0.4	61
42	Familial hypercholesterolemia in a European Mediterranean population—Prevalence and clinical data from 2.5 million primary care patients. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1013-1022.	0.6	61
43	Long-term safety and tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: A multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. <i>Clinical Therapeutics</i> , 2005, 27, 174-184.	1.1	60
44	HDL Triglycerides: A New Marker of Metabolic and Cardiovascular Risk. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3151.	1.8	58
45	Polyunsaturated fatty acids down-regulate in vitro expression of the key intestinal cholesterol absorption protein NPC1L1: no effect of monounsaturated nor saturated fatty acids. <i>Journal of Nutritional Biochemistry</i> , 2010, 21, 518-525.	1.9	56
46	Fatty acid-binding protein 4 is associated with endothelial dysfunction in patients with type 2 diabetes. <i>Atherosclerosis</i> , 2010, 213, 329-331.	0.4	55
47	Human serum/plasma lipoprotein analysis by NMR: Application to the study of diabetic dyslipidemia. <i>Progress in Nuclear Magnetic Resonance Spectroscopy</i> , 2013, 70, 1-24.	3.9	55
48	Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. <i>Aids</i> , 2006, 20, 1675-1677.	1.0	54
49	Management of Dyslipidemia in the Metabolic Syndrome. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 39-58.	1.0	54
50	Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. <i>Heart</i> , 2021, 107, 1369-1375.	1.2	53
51	Intestinal fatty acid binding protein polymorphism at codon 54 is not associated with postprandial responses to fat and glucose tolerance tests in healthy young Europeans. Results from EARS II participants. <i>Atherosclerosis</i> , 2000, 152, 317-325.	0.4	51
52	Apolipoprotein and apolipoprotein receptor genes, blood lipids and disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2003, 6, 177-187.	1.3	51
53	FABP4 Induces Vascular Smooth Muscle Cell Proliferation and Migration through a MAPK-Dependent Pathway. <i>PLoS ONE</i> , 2013, 8, e81914.	1.1	51
54	Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels—The zero-LDL hypothesis. <i>Journal of Clinical Lipidology</i> , 2018, 12, 292-299.e3.	0.6	51

#	ARTICLE	IF	CITATIONS
55	Effects of soluble fiber (<i>Plantago ovata</i> husk) on plasma lipids, lipoproteins, and apolipoproteins in men with ischemic heart disease. <i>American Journal of Clinical Nutrition</i> , 2007, 85, 1157-1163.	2.2	50
56	Plasma Fatty Acid-Binding Protein 4 Increases with Renal Dysfunction in Type 2 Diabetic Patients without Microalbuminuria. <i>Clinical Chemistry</i> , 2008, 54, 181-187.	1.5	49
57	Protease Inhibitor-Associated Dyslipidemia in HIV-Infected Patients Is Strongly Influenced by the APOA5 1131T>C Gene Variation. <i>Clinical Chemistry</i> , 2006, 52, 1914-1919.	1.5	48
58	Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1448-1457.	0.6	48
59	Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. <i>Aids</i> , 2004, 18, 819-821.	1.0	46
60	HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: The role of monocyte chemoattractant protein-1. <i>Cytokine</i> , 2006, 34, 51-55.	1.4	46
61	Characterization of ¹ H NMR Plasma Glycoproteins as a New Strategy To Identify Inflammatory Patterns in Rheumatoid Arthritis. <i>Journal of Proteome Research</i> , 2018, 17, 3730-3739.	1.8	46
62	Oxidized to non-oxidized lipoprotein ratios are associated with arteriosclerosis and the metabolic syndrome in diabetic patients. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, 380-387.	1.1	45
63	Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain. <i>Clinical Therapeutics</i> , 2017, 39, 771-786.e3.	1.1	45
64	Genetically Driven Hyperglycemia Increases Risk of Coronary Artery Disease Separately From Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, 687-693.	4.3	45
65	LDL Receptor Regulates the Reverse Transport of Macrophage-Derived Unesterified Cholesterol via Concerted Action of the HDL-LDL Axis. <i>Circulation Research</i> , 2020, 127, 778-792.	2.0	45
66	In vitro oxidised HDL is recognised by the scavenger receptor of macrophages: implications for its protective role in vivo. <i>Atherosclerosis</i> , 1994, 105, 179-189.	0.4	44
67	The Circulating GRP78/BiP Is a Marker of Metabolic Diseases and Atherosclerosis: Bringing Endoplasmic Reticulum Stress into the Clinical Scenario. <i>Journal of Clinical Medicine</i> , 2019, 8, 1793.	1.0	40
68	APOH is increased in the plasma and liver of type 2 diabetic patients with metabolic syndrome. <i>Atherosclerosis</i> , 2010, 209, 201-205.	0.4	38
69	Autosomal Recessive Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2018, 71, 279-288.	1.2	38
70	Lipoprotein(a) and the significance of the association between platelet glycoprotein IIIa polymorphisms and the risk of premature myocardial infarction. <i>Atherosclerosis</i> , 1998, 140, 155-159.	0.4	37
71	Cocoa, Hazelnuts, Sterols and Soluble Fiber Cream Reduces Lipids and Inflammation Biomarkers in Hypertensive Patients: A Randomized Controlled Trial. <i>PLoS ONE</i> , 2012, 7, e31103.	1.1	37
72	Prevalence of and predictors of bicuspid aortic valves in patients with dilated aortic roots. <i>American Journal of Cardiology</i> , 2003, 91, 619-622.	0.7	35

#	ARTICLE	IF	CITATIONS
73	High-density lipoprotein concentrations relate to the clinical course of HIV viral load in patients undergoing antiretroviral therapy. <i>Aids</i> , 2003, 17, 1173-1178.	1.0	35
74	Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2016, 28, 71-78.	0.4	35
75	Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia. <i>Advances in Therapy</i> , 2019, 36, 1786-1811.	1.3	35
76	Fatty acid binding protein 4 (FABP4) as a potential biomarker reflecting myocardial lipid storage in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, 12-21.	1.5	35
77	Low-density lipoprotein metabolism in rats treated with cyclosporine. <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 678-683.	1.5	34
78	Prevalence of Dementia in a Semi-Rural Population of Catalunya, Spain. <i>Neuroepidemiology</i> , 1996, 15, 33-41.	1.1	34
79	Exogenous FABP4 induces endoplasmic reticulum stress in HepG2 liver cells. <i>Atherosclerosis</i> , 2016, 249, 191-199.	0.4	34
80	The Apolipoprotein AV Gene and Diurnal Triglyceridaemia in Normolipidaemic Subjects. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 517-21.	1.4	33
81	Short-term Efficacy and Safety of Extended-release Fluvastatin in a Large Cohort of Elderly Patients. <i>The American Journal of Geriatric Cardiology</i> , 2003, 12, 225-231.	0.7	33
82	FABP4 inhibitor BMS309403 decreases saturated-fatty-acid-induced endoplasmic reticulum stress-associated inflammation in skeletal muscle by reducing p38 MAPK activation. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2018, 1863, 604-613.	1.2	33
83	Incidence of Cardiovascular Disease in Patients with Familial Hypercholesterolemia Phenotype: Analysis of 5 Years Follow-Up of Real-World Data from More than 1.5 Million Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 1080.	1.0	33
84	Oxidized Lipoproteins Including HDL and Their Lipid Peroxidation Products Inhibit TNF- α Secretion by THP-1 Human Macrophages. <i>Free Radical Biology and Medicine</i> , 1997, 23, 658-667.	1.3	32
85	The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. <i>Atherosclerosis</i> , 2008, 199, 147-153.	0.4	32
86	Long-term exposure to PM10 above WHO guidelines exacerbates COVID-19 severity and mortality. <i>Environment International</i> , 2022, 158, 106930.	4.8	32
87	Is there a role for lifestyle changes in cardiovascular prevention? What, when and how?. <i>Atherosclerosis Supplements</i> , 2017, 26, 2-15.	1.2	31
88	New perspectives on CKD-induced dyslipidemia. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 967-976.	1.5	31
89	Platelet function in patients with familial hypertriglyceridemia: Evidence that platelet reactivity is modulated by apolipoprotein E content of very-low-density lipoprotein particles. <i>Metabolism: Clinical and Experimental</i> , 2000, 49, 942-949.	1.5	30
90	Adipose-Derived Fatty Acid-Binding Proteins Plasma Concentrations Are Increased in Breast Cancer Patients. <i>Oncologist</i> , 2017, 22, 1309-1315.	1.9	29

#	ARTICLE	IF	CITATIONS
91	Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain. <i>Atherosclerosis</i> , 2019, 287, 89-92.	0.4	29
92	FABP4 predicts atherogenic dyslipidemia development. The PREDIMED study. <i>Atherosclerosis</i> , 2012, 222, 229-234.	0.4	28
93	APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis. <i>Atherosclerosis</i> , 2015, 240, 98-104.	0.4	28
94	New insights into circulating FABP4: Interaction with cytokeratin 1 on endothelial cell membranes. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 2966-2974.	1.9	28
95	Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases. <i>Cardiovascular Diabetology</i> , 2016, 15, 107.	2.7	28
96	Indicaciones de los inhibidores de PCSK9 en la práctica clínica. Recomendaciones de la Sociedad Española de Arteriosclerosis (SEA), 2019. <i>Clínica E Investigación En Arteriosclerosis</i> , 2019, 31, 128-139.	0.4	28
97	The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism. <i>Aids</i> , 2005, 19, 341-2.	1.0	28
98	Familial hypercholesterolemia in Morocco: first report of mutations in the LDL receptor gene. <i>Journal of Human Genetics</i> , 2003, 48, 199-203.	1.1	27
99	High-density lipoprotein cholesterol and apolipoprotein A1 levels strongly influence the reactivity of small peripheral arteries. <i>Atherosclerosis</i> , 2011, 216, 115-119.	0.4	27
100	Particle size measurement of lipoprotein fractions using diffusion-ordered NMR spectroscopy. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 402, 2407-2415.	1.9	27
101	Functional analysis of LDLR promoter and 5' UTR mutations in subjects with clinical diagnosis of familial hypercholesterolemia. <i>Human Mutation</i> , 2011, 32, 868-872.	1.1	26
102	Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets. <i>Current Cardiology Reports</i> , 2020, 22, 66.	1.3	26
103	FABP4 plasma levels are increased in familial combined hyperlipidemia. <i>Journal of Lipid Research</i> , 2010, 51, 1173-1178.	2.0	26
104	HDL derived from the different phases of conjugated diene formation reduces membrane fluidity and contributes to a decrease in free cholesterol efflux from human THP-1 macrophages. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2003, 1633, 143-148.	1.2	25
105	Surface fitting of 2D diffusion-edited 1H NMR spectroscopy data for the characterisation of human plasma lipoproteins. <i>Metabolomics</i> , 2011, 7, 572-582.	1.4	25
106	Is complying with the recommendations of sodium intake beneficial for health in individuals at high cardiovascular risk? Findings from the PREDIMED study. <i>American Journal of Clinical Nutrition</i> , 2015, 101, 440-448.	2.2	25
107	Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk. <i>Clinical Science</i> , 2015, 128, 877-882.	1.8	25
108	Lipoprotein hydrophobic core lipids are partially extruded to surface in smaller HDL: "herniated" HDL, a common feature in diabetes. <i>Scientific Reports</i> , 2016, 6, 19249.	1.6	25

#	ARTICLE	IF	CITATIONS
109	Cytotoxic effects of the lipid peroxidation product 2,4-decadienal in vascular smooth muscle cells. <i>Atherosclerosis</i> , 2003, 169, 245-250.	0.4	24
110	Máxima reducción de colesterol unido a lipoproteínas de baja densidad alcanzable con combinaciones farmacológicas. Cuando 50 más 20 suma 60. <i>Revista Española De Cardiología</i> , 2016, 69, 342-343.	0.6	24
111	Tumor necrosis factor-alpha -1031 T/C polymorphism is associated with smaller and more proatherogenic low density lipoprotein particles in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 1697-703.	1.0	24
112	The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study. <i>International Journal of Cardiology</i> , 2022, 361, 116-123.	0.8	24
113	In Vitro Biocompatibility of Surface-Modified Porous Alumina Particles for HepG2 Tumor Cells: Toward Early Diagnosis and Targeted Treatment. <i>ACS Applied Materials & Interfaces</i> , 2015, 7, 18600-18608.	4.0	23
114	Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients. <i>Atherosclerosis</i> , 2015, 238, 213-219.	0.4	23
115	Número de pacientes candidatos a recibir inhibidores de la PCSK9 según datos de 2,5 millones de participantes de la práctica clínica real. <i>Revista Española De Cardiología</i> , 2018, 71, 1010-1017.	0.6	23
116	Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. <i>Atherosclerosis Supplements</i> , 2020, 42, e49-e58.	1.2	23
117	How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?. <i>Atherosclerosis</i> , 2017, 262, 107-112.	0.4	22
118	Molecular basis of the familial chylomicronemia syndrome in patients from the National Dyslipidemia Registry of the Spanish Atherosclerosis Society. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1482-1492.e3.	0.6	22
119	Retinoic acid induces PGI synthase expression in human endothelial cells. <i>Journal of Lipid Research</i> , 2008, 49, 1707-1714.	2.0	21
120	Prox-1 and FOXC2 gene expression in adipose tissue: A potential contributory role of the lymphatic system to familial combined hyperlipidaemia. <i>Atherosclerosis</i> , 2009, 206, 343-345.	0.4	21
121	Pitavastatin in cardiometabolic disease: therapeutic profile. <i>Cardiovascular Diabetology</i> , 2013, 12, S2.	2.7	21
122	The stromal derived factor-1 mutated allele (SDF1-3'â€²A) is associated with a lower incidence of atherosclerosis in HIV-infected patients. <i>Aids</i> , 2005, 19, 1877-1883.	1.0	20
123	Increased concentrations of circulating vitamin E in carriers of the apolipoprotein A5 gene ϵ 1131T>C variant and associations with plasma lipids and lipid peroxidation. <i>Journal of Lipid Research</i> , 2007, 48, 2506-2513.	2.0	20
124	Autosomal recessive hypercholesterolemia in Spanish kindred due to a large deletion in the ARH gene. <i>Molecular Genetics and Metabolism</i> , 2007, 92, 243-248.	0.5	20
125	Sonographic evaluation of Achilles tendons and carotid atherosclerosis in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2009, 204, 345-347.	0.4	20
126	Nuclear Magnetic Resonance Lipoprotein Subclasses and the APOE Genotype Influence Carotid Atherosclerosis in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2010, 37, 2259-2267.	1.0	20

#	ARTICLE	IF	CITATIONS
127	Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry. <i>Atherosclerosis</i> , 2020, 299, 24-31.	0.4	20
128	Pitavastatin “ from clinical trials to clinical practice. <i>Atherosclerosis Supplements</i> , 2010, 11, 15-22.	1.2	19
129	Parallel evolution of circulating FABP4 and NT-proBNP in heart failure patients. <i>Cardiovascular Diabetology</i> , 2013, 12, 72.	2.7	19
130	Increasing long-chain n-3PUFA consumption improves small peripheral artery function in patients at intermediate“high cardiovascular risk. <i>Journal of Nutritional Biochemistry</i> , 2014, 25, 642-646.	1.9	19
131	Effectiveness of probucol in reducing plasma low-density lipoprotein cholesterol oxidation in hypercholesterolemia. <i>American Journal of Cardiology</i> , 1991, 68, 863-867.	0.7	18
132	Effect of malabsorption on nutritional status and resting energy expenditure in HIV-infected patients. <i>Aids</i> , 1998, 12, 1965-1972.	1.0	18
133	Low-density lipoprotein (LDL) binds to a G-protein coupled receptor in human platelets. <i>Atherosclerosis</i> , 2001, 155, 99-112.	0.4	18
134	Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: A 12-week, multicenter, randomized, open-label, parallel-group study. <i>Clinical Therapeutics</i> , 2008, 30, 84-97.	1.1	18
135	Heterozygous Familial Hypercholesterolaemic Patients have Increased Arterial Stiffness, as Determined using the Augmentation Index. <i>Journal of Atherosclerosis and Thrombosis</i> , 2011, 18, 1110-1116.	0.9	18
136	Should We Forget About Low-Density Lipoprotein Cholesterol?. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1228-1229.	1.2	18
137	Autosomal recessive hypercholesterolemia in Spain. <i>Atherosclerosis</i> , 2018, 269, 1-5.	0.4	18
138	Detecting familial hypercholesterolemia earlier in life by actively searching for affected children:The DECOPIN project. <i>Atherosclerosis</i> , 2018, 278, 210-216.	0.4	18
139	Substituting non-HDL cholesterol with LDL as a guide for lipid-lowering therapy increases the number of patients with indication for therapy. <i>Atherosclerosis</i> , 2013, 226, 471-475.	0.4	17
140	The apolipoprotein A5 gene “1131T”C polymorphism affects vitamin E plasma concentrations in type 2 diabetic patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 453-7.	1.4	16
141	Akt and ERK/Nrf2 activation by PUFA oxidation-derived aldehydes upregulates FABP4 expression in human macrophages. <i>Atherosclerosis</i> , 2013, 230, 216-222.	0.4	16
142	Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. <i>Cardiovascular risk perception. Clínica E Investigaci3n En Arteriosclerosis</i> , 2014, 26, 274-284.	0.4	16
143	A Comparison of Lifestyle, Genetic, Bioclinical and Biochemical Variables of Offspring with and without Family Histories of Premature Coronary Heart Disease: The Experience of the European Atherosclerosis Research Studies. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1999, 6, 183-188.	3.1	15
144	Additive Effects of the PPAR3, APOE, and FABP-2 Genes in Increasing Daylong Triglycerides of Normolipidemic Women to Concentrations Comparable to Those in Men. <i>Clinical Chemistry</i> , 2005, 51, 864-871.	1.5	15

#	ARTICLE	IF	CITATIONS
145	Prevalence of plasma lipid abnormalities and its association with glucose metabolism in Spain: The di@bet.es study. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2014, 26, 107-114.	0.4	15
146	Simvastatin Increases Fibulin-2 Expression in Human Coronary Artery Smooth Muscle Cells via RhoA/Rho-Kinase Signaling Pathway Inhibition. <i>PLoS ONE</i> , 2015, 10, e0133875.	1.1	15
147	Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach. <i>European Journal of Human Genetics</i> , 2015, 23, 381-387.	1.4	15
148	APOA5 genetic and epigenetic variability jointly regulate circulating triacylglycerol levels. <i>Clinical Science</i> , 2016, 130, 2053-2059.	1.8	15
149	Assessment of arterial stiffness variables in patients with rheumatoid arthritis: A mediation analysis. <i>Scientific Reports</i> , 2019, 9, 4543.	1.6	15
150	Cocientes lipoproteicos: significado fisiol3gico y utilidad clínica de los Índices aterogénicos en prevenci3n cardiovascular. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2010, 22, 25-32.	0.4	14
151	Circulating FABP4 and FABP5 Levels Are Differently Linked to OSA Severity and Treatment. <i>Sleep</i> , 2013, 36, 1831-1837.	0.6	14
152	Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children. <i>Journal of Clinical Lipidology</i> , 2018, 12, 211-218.	0.6	14
153	Autosomal dominant hypercholesterolemia in Catalonia: Correspondence between clinical-biochemical and genetic diagnostics in 967 patients studied in a multicenter clinical setting. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1452-1462.	0.6	14
154	Glycoprotein Profile Assessed by 1H-NMR as a Global Inflammation Marker in Patients with HIV Infection. A Prospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1344.	1.0	14
155	Dietary intake and lipid levels in Norwegian and Spanish children with familial hypercholesterolemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1299-1307.	1.1	14
156	Mechanisms for Regulating Platelet High Density Lipoprotein Type3 Binding Sites. <i>Thrombosis Research</i> , 1999, 94, 33-44.	0.8	13
157	Cambios de estilo de vida disminuyen las concentraciones plasmáticas de FABP4 en pacientes con riesgo cardiovascular. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 152-157.	0.6	13
158	Even low physical activity levels improve vascular function in overweight and obese postmenopausal women. <i>Menopause</i> , 2013, 20, 1036-1042.	0.8	13
159	Negative effect of a low-carbohydrate, high-protein, high-fat diet on small peripheral artery reactivity in patients with increased cardiovascular risk. <i>British Journal of Nutrition</i> , 2013, 109, 1241-1247.	1.2	13
160	Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. <i>Journal of Nutrition</i> , 2018, 148, 285-297.	1.3	13
161	Altered HDL Remodeling and Functionality in Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2018, 71, 466-468.	1.2	13
162	Palmitate decreases migration and proliferation and increases oxidative stress and inflammation in smooth muscle cells: role of the Nrf2 signaling pathway. <i>American Journal of Physiology - Cell Physiology</i> , 2019, 316, C888-C897.	2.1	13

#	ARTICLE	IF	CITATIONS
163	Extracellular FABP4 uptake by endothelial cells is dependent on cytokeratin 1 expression. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2019, 1864, 234-244.	1.2	13
164	Actualizaci3n de las tablas de planificaci3n terap3utica hipocolesterolemiantes orientadas a la obtenci3n de los objetivos terap3uticos. <i>Cl3nica E Investigaci3n En Arteriosclerosis</i> , 2019, 31, 271-277.	0.4	13
165	Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess. <i>Gynecological Endocrinology</i> , 2011, 27, 935-939.	0.7	12
166	HPS2-THRIVE results: Bad for niacin/laropiprant, good for ezetimibe?. <i>Atherosclerosis</i> , 2013, 229, 449-450.	0.4	12
167	AICAR Protects against High Palmitate/High Insulin-Induced Intramyocellular Lipid Accumulation and Insulin Resistance in HL-1 Cardiac Cells by Inducing PPAR-Target Gene Expression. <i>PPAR Research</i> , 2015, 2015, 1-12.	1.1	12
168	Body mass index correlates with atherogenic lipoprotein profile even in nonobese, normoglycemic, and normolipidemic healthy men. <i>Journal of Clinical Lipidology</i> , 2015, 9, 824-831.e1.	0.6	12
169	Variables associated with subclinical atherosclerosis in a cohort of rheumatoid arthritis patients: Sex-specific associations and differential effects of disease activity and age. <i>PLoS ONE</i> , 2018, 13, e0193690.	1.1	12
170	Plasma expression of microRNA-425-5p and microRNA-451a as biomarkers of cardiovascular disease in rheumatoid arthritis patients. <i>Scientific Reports</i> , 2021, 11, 15670.	1.6	12
171	Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease. <i>Biomedicines</i> , 2022, 10, 197.	1.4	12
172	Aldehydes mediate tissue factor induction: A possible mechanism linking lipid peroxidation to thrombotic events. <i>Journal of Cellular Physiology</i> , 2004, 198, 230-236.	2.0	11
173	FABP4 plasma levels are increased in familial combined hyperlipidemia. <i>Journal of Lipid Research</i> , 2010, 51, 1173-1178.	2.0	11
174	Lipoprotein profile assessed by 2D-1H-NMR and subclinical atherosclerosis in children with familial hypercholesterolaemia. <i>Atherosclerosis</i> , 2018, 270, 117-122.	0.4	11
175	Est3ndares SEA 2022 para el control global del riesgo cardiovascular. <i>Cl3nica E Investigaci3n En Arteriosclerosis</i> , 2022, 34, 130-179.	0.4	11
176	Plasma lipoprotein alterations in patients with chronic hepatocellular liver disease resulting from alcohol abuse: effects of alcohol intake cessation. <i>Journal of Hepatology</i> , 1994, 21, 704-709.	1.8	10
177	Hepatic production of apolar aldehydes in rats with carbon tetrachloride-induced cirrhosis. <i>Molecular and Cellular Biochemistry</i> , 1999, 198, 57-60.	1.4	10
178	Two novel single nucleotide polymorphisms in the promoter of the Cellular Retinoic Acid Binding Protein II gene (CRABP-II). <i>Molecular and Cellular Probes</i> , 2003, 17, 21-23.	0.9	10
179	Association of a polymorphism in the promoter of the cellular retinoic acid-binding protein II gene (CRABP2) with increased circulating low-density lipoprotein cholesterol. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 615-20.	1.4	10
180	Small artery dilation and endothelial markers in cardiovascular risk patients. <i>European Journal of Clinical Investigation</i> , 2012, 42, 34-41.	1.7	10

#	ARTICLE	IF	CITATIONS
181	The pleiotropic role of HDL in autoimmune diseases. <i>Clínica E Investigación En Arteriosclerosis</i> , 2015, 27, 97-106.	0.4	10
182	Number of Patients Eligible for PCSK9 Inhibitors Based on Real-world Data From 2.5 Million Patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 1010-1017.	0.4	10
183	Review of the scientific evolution of gene therapy for the treatment of homozygous familial hypercholesterolaemia: past, present and future perspectives. <i>Journal of Medical Genetics</i> , 2019, 56, 711-717.	1.5	10
184	Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 161-167.	0.4	10
185	Obesity Partially Mediates the Diabetogenic Effect of Lowering LDL Cholesterol. <i>Diabetes Care</i> , 2022, 45, 232-240.	4.3	10
186	Two Variants in the Fibulin2 Gene Are Associated with Lower Systolic Blood Pressure and Decreased Risk of Hypertension. <i>PLoS ONE</i> , 2012, 7, e43051.	1.1	9
187	FABP4 plasma concentrations are determined by acquired metabolic derangements rather than genetic determinants. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015, 25, 875-880.	1.1	9
188	Estimating Cardiovascular Risk in Spain by the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 417-425.	0.4	9
189	Impact of epidermal fatty acid binding protein on 2D-NMR assessed atherogenic dyslipidemia and related disorders. <i>Journal of Clinical Lipidology</i> , 2016, 10, 330-338.e2.	0.6	9
190	Valor de los parámetros lipídicos y apoproteicos para la detección de hipercolesterolemia familiar en la infancia. Proyecto DECOPIN. <i>Clínica E Investigación En Arteriosclerosis</i> , 2018, 30, 170-178.	0.4	9
191	Derivation and validation of SIDIAP-FHP score: A new risk model predicting cardiovascular disease in familial hypercholesterolemia phenotype. <i>Atherosclerosis</i> , 2020, 292, 42-51.	0.4	9
192	Documento de consenso de un grupo de expertos de la Sociedad Española de Arteriosclerosis (SEA) sobre el uso clínico de la resonancia magnética nuclear en el estudio del metabolismo lipoproteico (Liposcale). <i>Clínica E Investigación En Arteriosclerosis</i> , 2020, 32, 219-229.	0.4	9
193	Hepatic Lipidomics and Molecular Imaging in a Murine Non-Alcoholic Fatty Liver Disease Model: Insights into Molecular Mechanisms. <i>Biomolecules</i> , 2020, 10, 1275.	1.8	9
194	Serum glycoproteins A and B assessed by 1H-NMR in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2021, 330, 1-7.	0.4	9
195	Vitamin A is linked to the expression of the AI-CIII-AIV gene cluster in familial combined hyperlipidemia. <i>Journal of Lipid Research</i> , 1999, 40, 426-431.	2.0	9
196	Effect of the long-term regular intake of virgin olive oil on the phenolic metabolites in human fasting plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 53, 68-74.	1.4	8
197	Hipercolesterolemia familiar en la infancia y la adolescencia: una realidad oculta. <i>Clínica E Investigación En Arteriosclerosis</i> , 2017, 29, 129-140.	0.4	8
198	Causas de no consecución del objetivo terapéutico del colesterol de las lipoproteínas de baja densidad en pacientes de alto y muy alto riesgo vascular controlados en Unidades de Lípidos y Riesgo Vascular. Estudio EROMOT. <i>Clínica E Investigación En Arteriosclerosis</i> , 2018, 30, 1-9.	0.4	8

#	ARTICLE	IF	CITATIONS
199	Estándares SEA 2019 para el control global del riesgo cardiovascular. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2019, 31, 1-43.	0.4	8
200	Analysis of LDL and HDL size and number by nuclear magnetic resonance in a healthy working population: The LipoLab Study. <i>International Journal of Clinical Practice</i> , 2021, 75, e13610.	0.8	8
201	Physicochemical changes in HDL3 after bezafibrate treatment: influence on free cholesterol efflux from human fibroblasts. <i>Cardiovascular Drugs and Therapy</i> , 1997, 11, 653-658.	1.3	7
202	Maximum Low-density Lipoprotein Cholesterol Lowering Capacity Achievable With Drug Combinations. When 50 Plus 20 Equals 60. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 342-343.	0.4	7
203	Low-density lipoprotein net charge is a risk factor for atherosclerosis in lupus patients independent of lipid concentrations. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 480-487.	0.9	7
204	Glycoprotein Profile Measured by a 1H-Nuclear Magnetic Resonance Based on Approach in Patients with Diabetes: A New Robust Method to Assess Inflammation. <i>Life</i> , 2021, 11, 1407.	1.1	7
205	A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting. <i>Advances in Therapy</i> , 2022, 39, 1857-1870.	1.3	7
206	Generation of eight adjacent mutations in a single step using a site-directed mutagenesis kit. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 384-6.	1.4	6
207	Caveolin 3 deficiency myopathy associated with dyslipidemia: Treatment challenges and possible pathophysiological association. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1280-1283.	0.6	6
208	Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2019, 31, 128-139.	0.1	6
209	Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale®). <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2020, 32, 219-229.	0.1	6
210	Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients. <i>Atherosclerosis Supplements</i> , 2020, 42, e30-e34.	1.2	6
211	Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From ADA VINCI. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 941-953.	1.3	6
212	Molecular Requirements in the Recognition of Low-Density Lipoproteins (LDL) by Specific Platelet Membrane Receptors. <i>Thrombosis Research</i> , 2000, 99, 51-60.	0.8	5
213	Treatment of type IIb familial combined hyperlipidemia with the combination pravastatin-piperazine sultosilate. <i>European Journal of Pharmacology</i> , 2004, 496, 205-212.	1.7	5
214	Low-carbohydrate, high-protein, high-fat diet alters small peripheral artery reactivity in metabolic syndrome patients. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2014, 26, 58-65.	0.4	5
215	MTP gene polymorphisms and postprandial lipemia in familial combined hyperlipidemia: Effects of treatment with atorvastatin. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2014, 26, 49-57.	0.4	5
216	Altered Serum Metabolic Profile Assessed by Advanced 1H-NMR in Breast Cancer Patients. <i>Cancers</i> , 2021, 13, 4281.	1.7	5

#	ARTICLE	IF	CITATIONS
217	Relationship Between Fatty Acid Binding Protein 4 and Liver Fat in Individuals at Increased Cardiometabolic Risk. <i>Frontiers in Physiology</i> , 2021, 12, 781789.	1.3	5
218	Causes of failure to achieve the low density lipoprotein cholesterol therapeutic target in patients with high and very high vascular risk controlled in Lipid and Vascular Risk Units. EROMOT study. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2018, 30, 1-9.	0.1	4
219	Niveles plasmáticos de glucosa, triglicéridos, VLDL, leptina y resistina como potenciales biomarcadores de la grasa miocárdica en ratones. <i>Clínica E Investigación En Arteriosclerosis</i> , 2020, 32, 8-14.	0.4	4
220	Perfil clínico de los pacientes tratados con evolocumab en unidades de lípidos/medicina interna en España. Estudio observacional (RETOSS-IMU). <i>Clínica E Investigación En Arteriosclerosis</i> , 2020, 32, 183-192.	0.4	4
221	Ácido bempedoico. Mecanismo de acción y propiedades farmacocinéticas y farmacodinámicas. <i>Clínica E Investigación En Arteriosclerosis</i> , 2021, 33, 53-57.	0.4	4
222	Situación en 2020 de los requerimientos para la utilización de inhibidores de PCSK9 en España: resultados de una encuesta nacional. <i>Clínica E Investigación En Arteriosclerosis</i> , 2022, 34, 10-18.	0.4	4
223	MCF-7 Drug Resistant Cell Lines Switch Their Lipid Metabolism to Triple Negative Breast Cancer Signature. <i>Cancers</i> , 2021, 13, 5871.	1.7	4
224	Triglyceride-Rich Lipoproteins and Glycoprotein A and B Assessed by 1H-NMR in Metabolic-Associated Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , 2021, 12, 775677.	1.5	4
225	Effect of 13-cis-retinoic acid on the genetic expression profile of human umbilical vein endothelial cells (HUVECs) determined by microarray. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 829-34.	1.4	3
226	Lifestyle Changes Lower FABP4 Plasma Concentration in Patients With Cardiovascular Risk. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 152-157.	0.4	3
227	Design and evaluation of standard lipid prediction models based on 1H-NMR spectroscopy of human serum/plasma samples. <i>Metabolomics</i> , 2015, 11, 1394-1404.	1.4	3
228	Long-term effects of continuous positive airway pressure treatment on subclinical atherosclerosis in obstructive sleep apnoea syndrome. <i>Medicina Clínica (English Edition)</i> , 2016, 147, 1-6.	0.1	3
229	Dose wisely! How lipid-lowering undertreatment can lead to overtreatment. <i>Atherosclerosis</i> , 2016, 255, 126-127.	0.4	3
230	Update of therapeutic planning tables oriented towards obtaining therapeutic objectives. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2019, 31, 271-277.	0.1	3
231	Estimación del porcentaje de pacientes con enfermedad coronaria estable candidatos a recibir inhibidores de PCSK9. Respuesta. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 519-520.	0.6	3
232	Metabolismo de los triglicéridos y clasificación de las hipertrigliceridemias. <i>Clínica E Investigación En Arteriosclerosis</i> , 2021, 33, 1-6.	0.4	3
233	Efficacy of therapeutic lifestyle changes on lipid profiles assessed by NMR in children with familial and non-familial hypercholesterolemia. <i>Clínica E Investigación En Arteriosclerosis</i> , 2020, 32, 49-58.	0.4	3
234	Pregnancy homocysteine and cobalamin status predict childhood metabolic health in the offspring. <i>Pediatric Research</i> , 2023, 93, 633-642.	1.1	3

#	ARTICLE	IF	CITATIONS
235	Carotid intima-media thickness course in HIV-infected patients: beyond classical cardiovascular risk factors. <i>Aids</i> , 2007, 21, 1989-1990.	1.0	2
236	Familial hypercholesterolemia in childhood and adolescents: A hidden reality. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2017, 29, 129-140.	0.1	2
237	Genetic Confirmation of Monogenic Familial Hypercholesterolemia Advises a More Intensive Lipid-Lowering Approach. <i>JAMA Cardiology</i> , 2020, 5, 1452.	3.0	2
238	Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 348-353.	0.4	2
239	Massive data screening is a second opportunity to improve the management of patients with familial hypercholesterolemia phenotype. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2021, 33, 138-147.	0.1	2
240	Perfil lipoproteico determinado por resonancia magnética. El momento de su utilización clínica ha llegado. <i>Revista Espanola De Cardiologia</i> , 2022, 75, 5-8.	0.6	2
241	Evolution of Serum Acute-Phase Glycoproteins Assessed by 1H-NMR in HIV Elite Controllers. <i>Frontiers in Immunology</i> , 2021, 12, 730691.	2.2	2
242	<sc>HTE</sc> 3.0: Knowledge-based systems in cascade for familial hypercholesterolemia detection and dyslipidemia treatment. <i>Expert Systems</i> , 2022, 39, e12835.	2.9	2
243	Patrón de metilación en ADN de sujetos hipertriglicérmicos. <i>Clínica E Investigación En Arteriosclerosis</i> , 2022, 34, 27-32.	0.4	2
244	MicroRNA differential expression shared between rheumatoid arthritis and acute myocardial infarction: an exploratory study. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 886-887.	0.4	2
245	Interaction of oxidized low density lipoproteins with both apo B,E and scavenger receptors. A model for its production in vitro. <i>Clinica Chimica Acta</i> , 1992, 210, 93-108.	0.5	1
246	El gen de la apolipoproteína A5 se expresa en el intestino humano. <i>Clínica E Investigación En Arteriosclerosis</i> , 2008, 20, 129-134.	0.4	1
247	Análisis funcional de mutaciones en el promotor del LDLR y su relación con la hipercolesterolemia familiar. <i>Clínica E Investigación En Arteriosclerosis</i> , 2011, 23, 119-124.	0.4	1
248	Las Competencias Profesionales de Los Titulados en Medicina Mejoran Con la Introducción de un Programa de Simulación Con Pacientes Estandarizados y MINIC-CEX. <i>Procedia, Social and Behavioral Sciences</i> , 2015, 196, 25-29.	0.5	1
249	Intraabdominal fat redistribution in long-term continuous positive airway pressure treatment in obstructive sleep apnea patients. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 484-487.	0.1	1
250	The Zero-LDL Hypothesis. Towards Extremely Low LDL Concentrations. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 591-592.	0.4	1
251	Lipid and lipoprotein parameters for detection of familial hypercholesterolemia in childhood. The DECOPIN Project. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2018, 30, 170-178.	0.1	1
252	Estimated Percentage of Patients With Stable Coronary Heart Disease Candidates for PCSK9 Inhibitors. Response. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 519-520.	0.4	1

#	ARTICLE	IF	CITATIONS
253	Plasma glucose, triglycerides, VLDL, leptin and resistin levels as potential biomarkers for myocardial fat in mice. <i>Cl�nica E Investigaci�n En Arteriosclerosis (English Edition)</i> , 2020, 32, 8-14.	0.1	1
254	El rastreo masivo de datos es una segunda oportunidad para mejorar el manejo de los pacientes fenotipo de hipercolesterolemia familiar. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2021, 33, 138-147.	0.4	1
255	Tratar la dislipemia, algo m�s que dar estatinas. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2019, 31, 119-120.	0.4	1
256	Statistical mediation of the relationships between chronological age and lipoproteins by nonessential amino acids in healthy men. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 6169-6178.	1.9	1
257	Efecto del �cido 13-cis-retinoico sobre el perfil de expresi�n g�nica de c�lulas HUVEC (human umbilical) Tj ETQq1 1 0.784314 mgE 19, 129-135.	0.4	0
258	Intermediate levels of paraoxonase-1 activity are associated to lower intima-media thickness in HIV-infected patients. <i>Atherosclerosis</i> , 2008, 199, 232.	0.4	0
259	Los �cidos grasos poliinsaturados disminuyen la expresi�n in vitro de la prote�na NPC1L1, clave en la absorci�n intestinal de colesterol. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2008, 20, 200-206.	0.4	0
260	Influence of Inflammatory Variables on Intima-Media Thickness. <i>Stroke</i> , 2008, 39, e16.	1.0	0
261	La adici�n de leche fermentada suplementada con esteroles vegetales mejora el cumplimiento de los cambios en el estilo de vida en los pacientes hipercolesterol�micos. Estudio RECIPE. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2012, 24, 173-180.	0.4	0
262	Lipoprotein particle number and size distribution in apparently healthy spanish population according to sex and age, assessed by nuclear magnetic resonance. <i>Atherosclerosis</i> , 2017, 263, e86.	0.4	0
263	Results of the REVEAL study. Why should we not welcome a new lipid-lowering agent?. <i>Cl�nica E Investigaci�n En Arteriosclerosis (English Edition)</i> , 2017, 29, 278-279.	0.1	0
264	Resultados del estudio REVEAL. �Por qu� no debemos dar la bienvenida a un nuevo agente hipolipemiante?. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2017, 29, 278-279.	0.4	0
265	Treating dyslipidemia: something more than giving statins. <i>Cl�nica E Investigaci�n En Arteriosclerosis (English Edition)</i> , 2019, 31, 119-120.	0.1	0
266	Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 325-332.	1.0	0
267	Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU). <i>Cl�nica E Investigaci�n En Arteriosclerosis (English Edition)</i> , 2020, 32, 183-192.	0.1	0
268	Efficacy of therapeutic lifestyle changes on lipid profiles assessed by NMR in children with familial and non-familial hypercholesterolemia. <i>Cl�nica E Investigaci�n En Arteriosclerosis (English Edition)</i> , 2020, 32, 49-58.	0.1	0
269	Magnetic resonance-assessed lipoprotein profile. The time has come for its clinical use. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 75, 5-5.	0.4	0
270	DNA methylation pattern of hypertriglyceridemic subjects. <i>Cl�nica E Investigaci�n En Arteriosclerosis (English Edition)</i> , 2022, 34, 27-27.	0.1	0

#	ARTICLE	IF	CITATIONS
271	Situation in 2020 of the requirements for the use of PCSK9 inhibitors in Spain: Results of a national survey. <i>Clínica e Investigación en Arteriosclerosis (English Edition)</i> , 2022, 34, 10-18.	0.1	0
272	Letter to Editor: Increased Presence of Remnant Lipoprotein Cholesterol in The Hdl of Diabetic Subjects. <i>Annals of Clinical and Laboratory Science</i> , 2016, 46, 229-32.	0.2	0